相关实验视频
Updated: May 22, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
关于SERPINA3对人环素治疗和心血管功能障碍的反应的动态
Hanne M Boen1,2, Lobke L Pype3,4, Konstantinos Papadimitriou5
1Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, Antwerp, Belgium. hanne.boen@uantwerpen.be.
在安赛克林化疗 (AnC) 后,SERPINA3水平降低,但在患有中度癌症治疗相关心脏功能障碍 (CTRCD) 的患者中仍然升高. 这表明SERPINA3动态可能表明CTRCD风险.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
背景情况:
- 塞尔皮纳3是心力衰竭中潜在的预后生物标志物.
- 在癌症治疗相关心脏功能障碍 (CTRCD) 的癌症幸存者中观察到SERPINA3的升高.
研究的目的:
- 评估在接受抗环素化疗 (AnC) 的患者中循环SERPINA3水平的纵向变化.
- 调查SERPINA3动态和CTRCD的发展之间的关系.
主要方法:
- 55名癌症患者的前性队列研究,预计将在AnC.
- 在四个时间点测量了SERPINA3水平,心脏生物标志物 (热波宁I,NT-proBNP),心声学和GLS:化疗前,化疗后,3个月和化疗后12个月.
主要成果:
- 76.4%的患者在一年内发展出CTRCD.
- 总体SERPINA3水平在AnC后下降,最显著的是没有CTRCD的患者.
- 中度CTRCD患者的SERPINA3水平没有降低,与NT-proBNP相关.
结论:
- 循环中的SERPINA3水平在AnC之后动态变化.
- 在中度CTRCD中SERPINA3的升高表明其作为生物标志物的潜力.
- 需要在更大的队列中进一步验证,以确认SERPINA3在预测CTRCD中的作用.
更多相关视频
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Cardiac Performance
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pathophysiology of Heart Failure